FULLY FDA APPROVED
AR TE
YEPDA
WE’RE
5U
FOR THE TREATMENT OF ADULTS WITH NEWLY DIAGNOSED Ph+ CML-CP
THAT
CLOSE
99%
of TASIGNA® (nilotinib) patients
did not progress to AP/BC at 5 years1*
In ENESTnd, 95% of imatinib patients did not progress to AP/BC at 5 years1*
INDICATIONS
• TASIGNA® (nilotinib) is indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome–positive chronic myeloid leukemia
(Ph+ CML) in chronic phase. The effectiveness of TASIGNA is based on major molecular response and cytogenetic response rates
• TASI 9